Drug Profile
Research programme: Dicer-substrate siRNA therapeutics - Dicerna
Alternative Names: CTNNB1 DsiRNA; DCR BCAT; DCR-PCSK9; Dicer siRNA - Dicerna; DsiRNA - Dicerna; DsiRNA-EX conjugate - Dicerna; GalNAc-DsiRNA-EX conjugates; GalXC therapyLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Dicerna Pharmaceuticals
- Class Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antirheumatics; Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Haematological malignancies; Hypercholesterolaemia; Liver disorders; Solid tumours
- Discontinued Hepatitis C; Hyperlipidaemia; Rheumatoid arthritis; Type 2 diabetes mellitus
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Liver-disorders in USA (Parenteral)
- 28 Dec 2021 Dicerna Pharmaceuticals has been acquired by Novo Nordisk
- 28 Apr 2021 No recent reports of development identified for preclinical development in Hypercholesterolaemia in USA (SC, Injection)